The Fly | AEON

Focused Therapeutic Strategy: Aeon's exclusive focus on developing and commercializing prabotulinumtoxinA for therapeutic indications allows for specialized expertise, dedicated resources, and a concentrated effort to address unmet medical needs in neurological conditions.

Proven Active Pharmaceutical Ingredient: Leveraging prabotulinumtoxinA, an active ingredient with an established safety and efficacy profile from its aesthetic use, potentially de-risks clinical development and streamlines regulatory processes for therapeutic applications.

Large Addressable Market Potential: Aeon targets significant and growing therapeutic markets such as chronic migraine and cervical dystonia, representing substantial revenue opportunities and a high demand for effective treatment options.

Clinical Trial Failure: The success of Aeon Biopharma, Inc.'s lead product candidate, AI-001, is highly dependent on favorable results from ongoing and future clinical trials for its targeted therapeutic indications. Failure to demonstrate efficacy, safety, or achieve desired endpoints would significantly harm the company's prospects.

Regulatory Approval Uncertainty: Even with positive clinical trial data, there is no guarantee that AI-001 will receive necessary regulatory approvals from agencies like the FDA for its intended indications, which could delay or prevent commercialization.

Intense Market Competition: The therapeutic neurotoxin market is highly competitive with established players and new entrants, requiring Aeon Biopharma to differentiate AI-001 effectively to gain market share and achieve commercial success.